EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Belluscura's enterprise value is €27.53 Mil.
Belluscura's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €1.13 Mil. Therefore, Belluscura's EV-to-Revenue for today is 24.43.
The historical rank and industry rank for Belluscura's EV-to-Revenue or its related term are showing as below:
FRA:9VQ'
s EV-to-Revenue Range Over the Past 10 Years
Min: 7.67 Med: 155.9 Max: 1428.67
Current: 24.02
During the past 5 years, the highest EV-to-Revenue of Belluscura was 1428.67. The lowest was 7.67. And the median was 155.90.
FRA:9VQ's EV-to-Revenue is ranked worse than 90.59% of 829
companies
in the Medical Devices & Instruments industry
Industry Median: 3.25
vs FRA:9VQ: 24.02
As of today (2024-05-29), Belluscura's stock price is €0.168.
Belluscura's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was €0.01. Therefore, Belluscura's PS Ratio for today is 21.00.
Belluscura EV-to-Revenue Historical Data
The historical data trend for Belluscura's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Belluscura's EV-to-Revenue
For the Medical Devices subindustry, Belluscura's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belluscura's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Belluscura's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Belluscura's EV-to-Revenue falls into.
Belluscura's current Enterprise Value is €27.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Belluscura's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was €1.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belluscura's share price for today is €0.168.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belluscura EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Belluscura's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:9VQ has been successfully added to your 